- USDA Gets Tougher on Salmonella in Raw Breaded Chicken Products
- Fragments of Bird Flu Virus Found in 1 in 5 Milk Samples
- Clients Got HIV Through ‘Vampire Facial’ Microneedling Treatments
- Take the Stairs & Step Up to Longer Life
- ‘Drug Take Back Day’ is Saturday: Check for Leftover Opioids in Your Home
- Loneliness Can Shorten Lives of Cancer Survivors
- A Stolen Dog Feels Like Losing a Child, Study Finds
- Healthier Hearts in Middle Age Help Black Women’s Brains Stay Strong
- Better Scans Spot Hidden Inflammation in MS Patients
- Which Patients and Surgeries Are ‘High Risk’ for Seniors?
Rapivab Approved to Help Treat Flu
Rapivab (peramivir) has been approved by the U.S. Food and Drug Administration to treat influenza.
The intravenous drug inhibits an enzyme that releases viral particles from infected cells, the FDA explained Monday in a news release. Rapivab is approved for people 18 and older who have had flu symptoms for no more than two days.
Flu affects up to 20 percent of the American population each season, hospitalizing more than 200,000 people annually, the agency noted.
Rapivab’s safety and effectiveness were evaluated in a clinical study of almost 300 people with a confirmed case of the flu. Those given the newly approved drug had symptoms ease about 21 hours sooner than people who didn’t take the drug, the FDA said.
Common side effects included diarrhea and serious skin reactions. And the FDA stressed that Rapivab and other antiviral drugs are not substitutes for getting the annual flu vaccine.
Rapivab is produced by BioCryst Pharmaceuticals, based in Durham, N.C.
More information
Visit the FDA to learn more.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.